Kendall & Taylor Atkinson Foundation
Kendall & Taylor Atkinson Foundation
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for Kendall & Taylor Atkinson Foundation? Learn more here.
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.
About this organization
Mission
TO RAISE MONEY FOR CHARITABLE ALLOCATION.
About
ALLOCATIONS WERE MADE TO THE FANCONI ANEMIA RESEARCH FUND TO SUPPORT MEDICAL, SCIENTIFIC AND TREATMENT RESEARCH OF FANCONI ANEMIA AND ITS RELATED CANCERS:*$75,000 WAS ALLOCATED TO FUND RESEARCH ENTITLED "QUERCETIN CHEMOPREVENTION FOR SQUAMOUS CELL CARCINOMA IN PATIENTS WITH FANCONI ANEMIA." THIS RESEARCH IS BEING CONDUCTED BY DR. PARINDA MEHTA, MD, CINCINNATI CHILDREN'S HOSPITAL.EXCESSIVE TOXICITY FROM CHEMOTHERAPY AND RADIATION MAKES TREATMENT FOR SQUAMOUS CELL CARCINOMA (SCC) IN FA CHALLENGING AND OFTEN LEADS TO DISMAL OUTCOMES. THUS, THERE IS CLEARLY A NEED FOR A NEW APPROACH BOTH FOR PREVENTION AND/OR TREATMENT THAT HAS FEWER AND LESS SEVERE SIDE EFFECTS. PREVIOUS STUDIES CONDUCTED BY DR. MEHTA SHOWED THAT A NATURALLY OCCURRING ANTIOXIDANT, QUERCETIN, IS SAFE AND WELL TOLERATED IN PRE-HCT PATIENTS WITH FA. THIS STUDY WILL TEST WHETHER QUERCETIN PREVENTS THE DEVELOPMENT OF SCC IN POST-TRANSPLANT FA PATIENTS. THIS APPROACH IS EXPECTED TO WORK, AS QUERCETIN HAS BEEN REPORTED TO LEAD TO PREVENTION OF SCC IN MICE (NON-FA) AND DECREASED TUMOR GROWTH IN FA HEAD AND NECK CANCER CELL LINES. IN A PREVIOUS CLINICAL STUDY BY DR. MEHTA, EVIDENCE OF DECREASED DNA DAMAGE IN ORAL MUCOSA BRUSHINGS WAS OBSERVED IN PATIENTS WITH FA (PRE-HCT) AFTER TREATMENT WITH QUERCETIN FOR ONE MONTH. BASED ON THESE STRONG AND PROMISING DATA, THIS SECOND STUDY WILL TEST QUERCETIN TREATMENT FOR 6 MONTHS (WITH AN OPTION OF UP TO A TOTAL OF 2 YEARS) IN 20 POST-TRANSPLANT PATIENTS WITH FA. CLINICAL AND LABORATORY TESTS WILL CONFIRM THE BENEFICIAL EFFECT OF QUERCETIN. EXPECTED POSITIVE IMPACT IS THAT SUCCESS WILL LEAD TO A NEW PREVENTION STRATEGY FOR SCC IN POST-HCT PATIENTS WITH FA THAT WILL ELIMINATE OR AT LEAST DELAY THE DEVELOPMENT OF SCC.*$180,000 WAS ALLOCATED TO FUND RESEARCH ENTITLED "DEVELOPMENT OF A SAFE, COMPLETELY NON-GENOTOXIC ANTI-KIT ANTIBODY-BASED CONDITIONING REGIMEN FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FANCONI ANEMIA."THIS RESEARCH IS BEING CONDUCTED BY AGNIESZKA CZECHOWICZ, MD, PHD AT STANFORD UNIVERSITY. BONE MARROW TRANSPLANTATION HAS BEEN USED FOR 60-PLUS YEARS TO TREAT MORE THAN 1,000,000 PATIENTS SUFFERING FROM MANY TYPES OF BLOOD OR IMMUNE DISEASES, AND THIS THERAPY IS THE BEST CURRENT TREATMENT FOR FA PATIENTS EXPERIENCING BLOOD PROBLEMS. THIS PROCEDURE RELIES ON REPLACING SICK BLOOD-FORMING STEM CELLS IN PATIENTS WITH HEALTHY ONES FROM A DONOR, RESULTING IN A COMPLETELY NEW BLOOD SYSTEM. HOWEVER, THIS CURRENTLY REQUIRES USE OF IRRADIATION AND/OR CHEMOTHERAPY, WHICH CAN BE EXTREMELY HARMFUL, ESPECIALLY TO FA PATIENTS WHOSE CELLS CANNOT FIX DNA MISTAKES CAUSED BY THESE AGENTS. THIS STUDY WILL TEST WHETHER ANTIBODIES THAT CAN TARGET SPECIFIC CELLS OF THE BODY PROVIDE SAFE TURNOVER OF THE BONE MARROW AND ELIMINATE BONE MARROW DISEASE IN FA PATIENTS WITHOUT GENOTOXIC CONDITIONING. THIS TYPE OF THERAPY COULD NOT ONLY BE USED TO TREAT BLOOD PROBLEMS IN FA PATIENTS, BUT ALSO PREVENT THEM ALTOGETHER IF USED UPFRONT IN RECENTLY DIAGNOSED PATIENTS.*$30,000 WAS ALLOCATED TO FUND RESEARCH ENTITLED "PILOT STUDY OF METFORMIN FOR PATIENTS WITH FANCONI ANEMIA." THIS RESEARCH IS BEING CONDUCTED BY AKIKRO SHIMAMURA, MD, PHD, AND ELISSA FURTANI, MD, AT HARVARD MEDICAL SCHOOL/DANA-FARBER CANCER INSTITUTE. LOW BLOOD COUNTS DUE TO BONE MARROW FAILURE ARE A COMMON COMPLICATION OF FANCONI ANEMIA (FA) THAT AFFECT HEALTH AND QUALITY OF LIFE. METFORMIN IS AN FDA-APPROVED ORAL MEDICATION THAT HAS BEEN USED FOR MANY DECADES TO TREAT DIABETES AND INSULIN RESISTANCE. NEW EVIDENCE HAS SHOWN THAT THE DRUG IMPROVES BLOOD COUNTS IN MICE WITH FA AND THAT IT PROTECTS AGAINST DNA DAMAGE. OTHER LABORATORY STUDIES SUGGEST THAT METFORMIN MAY BE PROTECTIVE AGAINST ALDEHYDES, WHICH ARE TOXIC TO FA MICE AND TO FA PATIENTS. METFORMIN IS CURRENTLY BEING STUDIED IN OTHER CLINICAL TRIALS AS AN ANTI-AGING AND ANTI-CANCER DRUG, BUT IT IS NOT KNOWN HOW METFORMIN WILL AFFECT PEOPLE WITH FA. THIS STUDY WILL TEST WHETHER METFORMIN IMPROVES BLOOD COUNTS IN PEOPLE WITH FA. THE STUDY WILL ENROLL PARTICIPANTS BETWEEN THE AGES OF 6 TO 35 YEARS WHO HAVE NOT HAD A BONE MARROW TRANSPLANT.*$5,000 WAS ALLOCATED FOR SCHOLARSHIPS FOR FAMILIES AFFECTED BY FA TO ATTEND CAMP SUNSHINE. CAMP SUNSHINE PROVIDES RESPITE, SUPPORT, JOY, AND HOPE TO CHILDREN WITH LIFE-THREATENING ILLNESSES AND THEIR IMMEDIATE FAMILIES THROUGH THE VARIOUS STAGES OF THEIR JOURNEYS. DURING FANCONI ANEMIA WEEK AT CAMP, FAMILIES FIND SUPPORT AND ENCOURAGEMENT FROM OTHERS AFFECTED BY THIS DISEASE. IN ADDITION, THERE ARE IN-DEPTH SEMINARS PRESENTED BY A WIDE RANGE OF FA SPECIALISTS PRESENTING INFORMATION ON THE MOST CURRENT THERAPIES AND ADVANCEMENTS. THE PRESENTERS REMAIN AVAILABLE TO FAMILIES FOR INDIVIDUAL QUESTIONS AND CONSULTS.*ALLOCATIONS TO YOUTHROOTS, DENVER, CO$5,147 WAS ALLOCATED TO YOUTHROOTS TO FUND SCHOLARSHIPS FOR 8 LOW-INCOME STUDENTS TO PARTICIPATE IN THE YOUTHROOTS LEADERSHIP AND PHILANTHROPY PROGRAM.USING PHILANTHROPY AS A VEHICLE, YOUTHROOTS ENGAGES HIGH SCHOOL STUDENTS IN PERSONAL DEVELOPMENT, COMMUNITY PARTNERSHIPS AND INNOVATIVE VENTURES TO FOSTER LEADERSHIP, INTEGRITY AND SOCIAL ACTION, THEREFORE CULTIVATING A NETWORK OF THRIVING ADULTS WHO ENVISION A BETTER FUTURE AND REALIZE THEIR FULL HUMAN POTENTIAL.*ALLOCATIONS WERE MADE TO THE UNIVERSITY OF COLORADO FOUNDATION$50,000 WAS ALLOCATED TO THE UNIVERSITY OF COLORADO FOUNDATION FOR THE KENNETH R. ATKINSON MD, ENDOWED MEMORIAL SCHOLARSHIP AT THE UNIVERSITY OF COLORADO SCHOOL OF MEDICINE.THESE FUNDS WILL BE USED TO PROVIDE UNDERGRADUATE SCHOLARSHIP AWARDS FOR NEEDY STUDENTS ENROLLED IN THE SCHOOL OF MEDICINE AT THE UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS. SCHOLARSHIPS WILL BE GIVEN TO 4TH-YEAR MEDICAL STUDENTS WHOSE PLANS ARE TO PRACTICE PRIMARY CARE MEDICINE. RECIPIENTS WILL BE DETERMINED BASED ON BOTH FINANCIAL NEED AND ACADEMIC MERIT, AS DETERMINED BY THE UNIVERSITY. PREFERENCE WILL BE GIVEN TO STUDENTS PLANNING ON PRACTICING FAMILY MEDICINE IN THE STATE OF COLORADO AND THOSE WHO HAVE EXPRESSED INTEREST IN PROVIDING MEDICAL CARE TO HISTORICALLY UNDERSERVED OR MARGINALIZED COMMUNITIES.ALLOCATIONS WERE MADE TO LUBIRD'S LIGHT FOUNDATION. $25,000 WAS ALLOCATED TO THE LUBIRD'S LIGHT FOUNDATION TO GO TOWARD THE CONSTRUCTION OF AN ALL-INCLUSIVE PLAYGROUND AT THE STANLEY MARKETPLACE DEVELOPMENT IN DENVER, COLORADO.LUBIRD'S LIGHT FOUNDATION WAS FOUNDED TO BUILD MAGICAL INCLUSIVE PLAYGROUNDS FOR CHILDREN OF ALL NEEDS AND TO SUPPORT CHILDREN WITH RARE DISABILITIES. FUNDS PROVIDED BY KATA WILL HELP SUPPORT THE CONSTRUCTION OF A PLAYGROUND DESIGNED FOR USE BY ALL CHILDREN, REGARDLESS OF THEIR DISABILITY, AT THE STANLEY MARKETPLACE DEVELOPMENT IN DENVER, CO.ALLOCATIONS WERE MADE TO BREAD OF LIFE AFRICAN MINISTRIES (BOLAM). $5,152 WAS ALLOCATED TO BREAD OF LIFE AFRICAN MINISTRIES (BOLAM) FOR THE PURPOSE OF BUILDING A 3-CAR GARAGE AND SMALL GATE AT THE ENTRANCE TO THE RESIDENCY AREA AT KEIRUNGI CHILDREN'S VILLAGE.THE MAIN OBJECTIVE OF BOLAM IS TO REDUCE THE NUMBER OF CHILDREN LIVING ON THE STREETS IN UGANDA. BOLAM BUILT AND OPERATES KEIRUNGI CHILDREN'S VILLAGE IN SOUTHWEST UGANDA, MEETING THE HOLISTIC NEEDS OF ABANDONED CHILDREN IN A NURTURING ENVIRONMENT. A GARAGE TO KEEP THE VAN THAT KATA EARLIER PROVIDED FUNDING FOR WAS NEEDED TO PREVENT THEFT AND VANDALISM. ADDITIONALLY, THE GATE INTO THE RESIDENCY AREA WILL PROVIDE NEEDED SECURITY FOR THE CHILDREN LIVING THERE.
Interesting data from their 2020 990 filing
The non-profit's mission, as described in the filing, is “To raise money for charitable allocation.”.
When describing its duties, they were characterized as: “To raise money for charitable allocation.”.
- The non-profit has complied with legal regulations by reporting their state of operation as CO.
- The filing shows that the non-profit's address as of 2020 is 6192 E LONG CIR SO, CENTENNIAL, CO, 80112.
- As of 2020, the non-profit has reported a total of 0 employees on their form.
- Is not a private foundation.
- Expenses are between $250,000 and $500,000.
- Revenue is between $250,000 and $500,000.
- Revenue less expenses is -$54,387.
- The organization has 8 independent voting members.
- The organization was formed in 2006.
- The organization pays $0 in salary, compensation, and benefits to its employees.
- The organization pays $0 in fundraising expenses.